|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Curcumin and Apigenin – novel and promising therapeutics against chronic neuroinflammation in Alzheimer's disease显示文摘Alzheimer's disease is a progressive neurodegenerative disorder, characterized by deposition of amyloid beta, neurofibrillary tangles, astrogliosis and microgliosis, leading to neuronal dysfunction and loss in the brain. Current treatments for Alzheimer's disease primarily focus on enhancement of cholinergic transmission. However, these treatments are only symptomatic, and no disease-modifying drug is available for Alzheimer's disease patients. This review will provide an overview of the proven antioxidant, anti-inflammatory, anti-amyloidogenic, neuroprotective, and cognition-enhancing effects of curcumin and apigenin and discuss the potential of these compounds for Alzheimer's disease prevention and treatment. We suggest that these compounds might delay the onset of Alzheimer's disease or slow down its progression, and they should enter clinical trials as soon as possible. | Madhuri Venigalla Erika Gyengesi Gerald Münch | 2015 | Neural Regeneration Research2015，10，8： | 11 |
| 2 | Low dose oral curcumin is not effective in induction of remission in mild to moderate ulcerative colitis: Results from a randomized double blind placebo controlled trial显示文摘AIM To evaluate the role of oral curcumin in inducing clinical remission in patients with mild to moderate ulcerative colitis(UC).METHODS A prospective randomized double-blind placebo-controlled trial comparing the remission inducing effect of oral curcumin and mesalamine 2.4 g with placebo and mesalamine 2.4 g in patients of ulcerative colitis with mild to moderate severity was conducted from January 2003 to March 2005. The included patients received 1 capsule thrice a day of placebo or curcumin(150 mg) for 8 wk. Patients were evaluated clinically and endoscopically at 0,4 and 8 wk. The primary outcome was clinical remission at 8 wk and secondary outcomes were clinical response, mucosal healing and treatment failure at 8 wk. The primary analysis was intention to treat worst case scenario(ITT-WCS).RESULTS Of 300 patients with UC, 62 patients(curcumin: 29, placebo: 33) fulfilled the inclusion criteria and were randomized at baseline. Of these, 21 patients did not complete the trial, 41 patients(curcumin: 16, placebo: 25) finally completed 8 wk. There was no significant difference in rates of clinical remission(31.3% vs 27.3%, P = 0.75), clinical response(20.7% vs 36.4%, P = 0.18), mucosal healing(34.5% vs 30.3%, P = 0.72), and treatment failure(25% vs 18.5%, P = 0.59) between curcumin and placebo at 8 wk.CONCLUSION Low dose oral curcumin at a dose of 450 mg/d was ineffective in inducing remission in mild to moderate cases of UC. | Saurabh Kedia Vikram Bhatia Sandeep Thareja Sushil Garg Venigalla Pratap Mouli Sawan Bopanna Veena Tiwari Govind Makharia Vineet Ahuja | 2017 | World Journal of Gastrointestinal Pharmacology and Therapeutics2017，8，2： | 2 |
| 3 | Respiratory function in healthy late preterm infants delivered at 33 - 36 weeks of gestation 显示文摘 | McEvoy C Venigalla S Schilling D | 2013 | J Pediatr2013，162，3： | 1 |
| 4 | Advanced materials & powders显示文摘 | Sridhar Venigalla | 2000 | Amer Ceram Soc Bull2000，79，6： | 1 |
| 5 | Respiratory function in healthy late preterm infants delivered at 33-36 weeks of gestation显示文摘 | McEvoy C Venigalla S Schilling D et a1 | 2013 | J Pediatr2013，162，3： | 1 |
| 6 | Induction of CD4 + T -cell anergy and apoptosis by activated human B cells 显示文摘 | Tretter T Venigalla RK Eckstein V | 2008 | Blood2008，112，12： | 1 |
| 7 | Comparison of marginal adaptation of mineral trioxide aggregate,glass ionomer cement and intermediate restorative material as root-end filling materials,using scanning electron microscope:An in vitro study显示文摘 | Gundam S Patil J Venigalla BS | 2014 | J Conserv Dent2014，17，6： | 1 |
| 8 | Neonatal cholestasis 显示文摘 | Venigalla S Gourley GR | 2004 | Semin Perinatol2004，28，5： | 1 |
| 9 | Quantitative evaluation of apical extrusion of intracanal bacteria using K3, Mtwo, RaCe and protaper rotary systems: an in vitro study显示文摘 | Garlapati R Venigalla BS Patil JD | 2013 | I Conserv Dent2013，16，4： | 1 |
| 10 | Quantitative evalua- tion of apical extrusion of intracanal bacteria using K3, Mtwo, RaCe and ProTaper rotary systems: an in vitro study 显示文摘 | Garlapati R Venigalla BS Patil JD | 2013 | J Con- serv Dent2013，16，4： | 1 |
| 11 | Low-temperature hydrothermal synthesis of yttrium-doped zirconia powders 显示文摘 | TSUKADA T VENIGALLA S MORRONE A A | 1999 | Journal of the American Ceramic Society1999，82，5： | 1 |
| 12 | Respiratory function in healthy late preterm infants dclivered at 33-36 weeks of gestation显示文摘 | McEvoy C Venigalla S Schilling D | | 0，，03： | 1 |
| 13 | Quantitative evalua- tion of apical extrusion of intracanal bacteria using K3, Mtwo, RaCe and protaper rotary systems : An in vitro study 显示文摘 | Garlapati R Venigalla BS Patil JD | 2013 | J Con- serv Dent2013，16，4： | 1 |
| 14 | Defining the ATPase center of bacteriophage T4 DNA packaging machine:requirement for a catalytic glutamate residue in the large terminase protein gp17显示文摘 | Katherine R Goetzinger Venigalla B | 2003 | Molecular Microbiology2003，331，： | 1 |
| 15 | Display of a por A Peptide from Neisseria meningitidis on the Bacteriophage T4 capsid Surface 显示文摘 | Jenniger J Lara Abu-Shilbayeh Venigalla B R | 1997 | Infection and Immunity1997，，： | 1 |
| 16 | Functional analysis of the DNA-packaging/terminase protein gp17 from bacteriophage T4显示文摘 | Daniel K Venigalla B | 1988 | Molecular Microbiology1988，281，： | 1 |
| 17 | Ad- vanced Materials and Powders 显示文摘 | Mussier B H Venigalla S Johnson W C | 2000 | American Ceramic Society Bulletin2000，79，6： | 1 |
| 18 | 显示文摘 | Mussler B H Venigalla S Johnson W C | 2000 | Am Ceram Soc Bull2000，79，6： | 1 |
| 19 | Analysis of a large single-center experience with robot-assisted pyeloplasty显示文摘 | Tobis S Venigalla S Balakumaran K | | International Journal of Urology0，，： | 1 |
| 20 | Reduced CD4, CD25 Tcell sensitivity to the suppressive function of CD4+ , CD25 high,CD127-/low regulatory T cells in patients with active systemiclupuserythematosus显示文摘 | Venigalla RK Tretter T Krienke S | 2008 | Arthritis Rheum2008，58，7： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员